Robert J. Glynn, PhD, ScD
Professor of Medicine, Harvard Medical School
Senior Biostatistician, Brigham and Women’s Hospital
rglynn@rics.bwh.harvard.edu
Dr. Glynn earned a PhD in mathematics and an ScD in biostatistics. He is a Professor of Medicine at Harvard Medical School, Associate Professor of Biostatistics at HSPH, and a Biostatistician in the Divisions of Preventive Medicine, and Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women’s Hospital. He has been responsible for the design, interim monitoring, and analysis of numerous multi-center randomized trials, funded by the NIH, foundations, and industry, including JUPITER, PREVENT, VAL-MARC, HEART, and the ongoing CIRT trial, other large trials conducted by mail such as the Physicians’ Health Study II, and cluster-randomized trials of interventions such as academic detailing and other strategies to improve the quality of prescribing and adherence, such as the MI FREEE trial. His interim monitoring reports provided the key information that led to the decisions by independent data and safety monitoring boards to terminate both the PREVENT trial (NEJM 2003) and the JUPITER trial (NEJM 2008) because of convincing evidence of benefit to the enrolled participants, and to modify the duration of the MI FREEE trial (NEJM 2011).
Dr. Glynn has also led both randomized and observational studies that have clarified the shared and distinct risk factors and possible preventive approaches for venous and arterial thrombosis, including observational comparisons of the associations of dietary factors and other cardiovascular risk factors with incident venous thromboembolism, as well as randomized trials of the impact of aspirin, vitamin E, and statins on the incidence of venous thromboembolism.
MA: Boston College
PhD: Brandeis University
SM: Harvard School of Public Health
ScD: Harvard School of Public Health
Full Listing of Publications
- Analyzing missingness patterns in real-world data using the SMDI toolkit: application to a linked EHR-claims pharmacoepidemiology study October 19, 2024CONCLUSIONS: We were able to demonstrate the practical application of the SMDI toolkit in a real-world setting. Application of the SMDI toolkit and the resulting insights of potential missingness patterns can inform the choice of appropriate analytic methods and increase transparency of research methods in handling missing data. This type of approach can inform analytic […]Sudha R Raman
- Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents October 9, 2024No abstractSungho Bea
- A scalable approach to assess the safety of recently marketed systemic treatments for atopic dermatitis in clinical practice October 3, 2024Targeted systemic immune-modulating drugs (IMDs) to treat atopic dermatitis (AD) were highly efficacious in randomized trials. Trials with limited number of subjects leave questions about their safety. We describe a data and analytics structure for the production of timely, high-quality evidence on the comparative safety of recently approved IMDs in patients with AD in clinical […]Maria C Schneeweiss
- Use of Censored Data Methods to Estimate Blood Pressure Percentiles in US Adults September 17, 2024Blood pressure (BP) levels are important modifiable risk factors for incident cardiovascular disease (CVD). However, many adults are on anti-hypertensive medication (MEDS) which lowers their BP but is a marker for increased CVD risk. To capture the association of BP and its treatment with risk, it is important to estimate BP levels in the absence […]Bernard Rosner
- The Healthy User Effect in Pharmacoepidemiology September 13, 2024The healthy user effect is a well-recognized bias in the field of pharmacoepidemiology and can be expected to overstate the effect of a preventive intervention when comparing long term users or "adherers" to non-users. Similar to the healthy worker effect observed in occupational epidemiology, the healthy user effect can be separated into a healthy initiator […]Oluwasolape Olawore